Group 1 - The core viewpoint of the article highlights the performance of the E Fund Healthcare Industry Mixed A Fund, which has shown significant returns over various time frames [1] - As of August 24, 2025, the latest net value of the fund is 4.7380 yuan, with a weekly return of -0.94%, a three-month return of 31.94%, and a year-to-date return of 55.55% [1] - The fund was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Medicine, Rejig Bio, Xin Li Tai, BeiGene-U, Hai Si Ke, and others, with a total holding percentage of 58.14% [1] - The fund manager is Yang Zhenshao, who oversees the investment strategy and portfolio management [1]

Core Insights - The core viewpoint of the news is the performance and holdings of the E Fund Healthcare Industry Mixed A Fund, highlighting its recent returns and key stock positions [1]. Fund Performance - The latest net value of E Fund Healthcare Industry Mixed A is 4.7830 yuan [1]. - The fund has achieved a weekly return of 3.57% [1]. - Over the past three months, the fund's return is 44.07% [1]. - Year-to-date, the fund has generated a return of 57.03% [1]. Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011 [1]. - As of June 30, 2025, the fund's total assets amount to 3.944 billion yuan [1]. - The fund is managed by Yang Zhenshao [1]. Top Holdings - The top ten stock holdings of the fund include: - Heng Rui Medicine - Hotgen Biotech - Xinlitai - BeiGene-U - Haizhi Science - Nocren Health-U - Yipinhong - Kelun Pharmaceutical - Shutaishen - Baili Tianheng [1]. - The combined proportion of the top ten holdings is 58.14% [1].

Core Viewpoint - E Fund Healthcare Industry Mixed A Fund (110023) has shown significant performance with a recent net value of 4.5530 CNY, despite a slight decline of 1.73% [1] Performance Summary - The fund's one-month return is 12.81%, ranking 628 out of 4566 in its category [1] - Over the past six months, the fund has achieved a return of 48.74%, ranking 108 out of 4413 [1] - Year-to-date, the fund's return stands at 49.47%, with a ranking of 158 out of 4375 [1] Holdings Summary - The top ten stock holdings of E Fund Healthcare Industry Mixed A account for a total of 58.14%, with the following key positions: - Heng Rui Medicine: 7.39% - Rejing Biology: 7.00% - Xinlitai: 6.73% - BeiGene-U: 6.47% - Haizhi Science: 6.00% - Nocren Health-U: 5.21% - Yipinhong: 5.08% - Kelun Pharmaceutical: 5.07% - Shutaishen: 5.05% - Baili Tianheng: 4.14% [1] Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion CNY [1] - The fund manager is Yang Zhenshao, who holds a PhD in Science and has experience as an investment manager, industry researcher, and assistant fund manager at E Fund [1]

Core Viewpoint - The E Fund Healthcare Industry Mixed A Fund has shown significant performance with a year-to-date return of 51.61% as of June 30, 2025, despite a recent weekly decline of 1.56% [1]. Fund Performance - The latest net value of the E Fund Healthcare Industry Mixed A is 4.6180 yuan [1]. - The fund has achieved a return of 38.35% over the past three months [1]. - The fund was established on January 28, 2011, and has a total scale of 3.944 billion yuan as of June 30, 2025 [1]. Holdings - The top ten stock holdings of the fund include: - 恒瑞医药 (Hengrui Medicine) - 热景生物 (Hotgen Biotech) - 信立泰 (Sihuan Pharmaceutical) - 百济神州-U (BeiGene) - 海思科 (Hisun Pharmaceutical) - 诺诚健华-U (Innovent Biologics) - 一品红 (Yipinhong) - 科伦药业 (Kelun Pharmaceutical) - 舒泰神 (Shutai Shen) - 百利天恒 (Baili Tianheng) - The combined proportion of the top ten holdings is 58.14% [1].

Core Viewpoint - E Fund Healthcare Industry Mixed A Fund (110023) has shown a recent decline in net value but has performed well over various time frames, indicating strong potential in the healthcare sector [1] Fund Performance - The latest net value of E Fund Healthcare Industry Mixed A is 4.6060 CNY, down by 2.62% [1] - The fund's one-month return is 16.23%, ranking 303 out of 4679 in its category [1] - Over the past six months, the fund has achieved a return of 52.37%, ranking 91 out of 4531 [1] - Year-to-date, the fund has returned 51.21%, ranking 135 out of 4490 [1] Holdings Overview - The top ten stock holdings of E Fund Healthcare Industry Mixed A account for a total of 58.14% of the portfolio [1] - Major holdings include: - Heng Rui Medicine (7.39%) - Rejoice Bio (7.00%) - Xin Li Tai (6.73%) - BeiGene-U (6.47%) - Hai Si Ke (6.00%) - Nuo Cheng Jian Hua-U (5.21%) - Yi Pin Hong (5.08%) - Ke Lun Pharmaceutical (5.07%) - Shu Tai Shen (5.05%) - Bai Li Tian Heng (4.14%) [1] Fund Background - E Fund Healthcare Industry Mixed A was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion CNY [1] - The fund manager is Yang Zhenshao, who holds a PhD in Science and has experience as an investment manager, industry researcher, and assistant fund manager at E Fund [1]

Core Viewpoint - The E Fund Healthcare Industry Mixed A Fund (110023) reported a profit of 535 million yuan in Q2 2025, with a weighted average profit per fund share of 0.4323 yuan, and a net value growth rate of 12.16% during the reporting period [3] Fund Performance - As of July 18, the fund's unit net value was 4.524 yuan, with a recent three-month net value growth rate of 34.04%, ranking 47 out of 138 comparable funds [4] - The fund's six-month net value growth rate was 54.03%, ranking 48 out of 138, and the one-year growth rate was 51.05%, ranking 46 out of 133 [4] - Over the past three years, the fund achieved a net value growth rate of 52.38%, ranking 7 out of 107 [4] Risk and Return Metrics - The fund's Sharpe ratio over the past three years was 0.4532, ranking 17 out of 105 comparable funds [9] - The maximum drawdown over the past three years was 24.99%, with the worst quarterly drawdown occurring in Q1 2021 at 24.73% [11] Investment Strategy - The fund underwent significant portfolio adjustments during the reporting period, reducing holdings in sectors like CXO and IVD, while concentrating investments in the innovative drug sector, based on a thorough analysis of the prospects for China's innovative drug industry [3] Fund Holdings - The fund's average stock position over the past three years was 92.35%, compared to an average of 86.91% for comparable funds, reaching a peak of 94.24% at the end of H1 2023 [14] - As of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, Recbio Technology, and BeiGene, with a concentration exceeding 60% for the top ten holdings over the past two years [18] Fund Size - As of the end of Q2 2025, the fund's total size was 3.944 billion yuan [15]

Group 1 - The core viewpoint of the news is that as of March 27, 2025, institutional investors hold a significant portion of Tiger Medical's A-shares, totaling 1.76 billion shares, which accounts for 20.31% of the company's total equity [1] - The top ten institutional investors collectively hold 14.86% of Tiger Medical's shares, with a decrease of 1.43 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, while five funds decreased their holdings, with a total reduction rate of 0.19% [2] - A total of 16 new public funds were disclosed this period, including notable funds such as E Fund CSI 300 Medical ETF and others [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.30% compared to the previous quarter [2]